Correction to: Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men (Prostate Cancer and Prostatic Diseases, (2024), 27, 1, (109-115), 10.1038/s41391-023-00703-0)

Correction to: Prostate Cancer and Prostatic Diseaseshttps://doi.org/10.1038/s41391-023-00703-0, published online 24 August 2023 Following the publication of this article, the authors noted an error in the number of patients listed as undergoing operation after receiving WVTT therapy. 10 patients were listed instead of 19—Table 4 has been updated to reflect this, as well as the relevant sections of text reporting this data. The authors confirm this change does not alter the primary outcomes of their study and apologise for any inconvenience caused to readers. Table 4 Occurrence and duration of postoperative adverse events. (Table presented.) Characteristic All patients Age < 65 years Age ≥ 65 years UTI, N (%) 8 (3.3%) 5 (3.5%) 3 (2.9%) 0.78 Sepsis, N (%) 0 (0%) 0 (0%) 0 (0%) Surgical Retreatment, N (%) 10 (4.2%) 6 (4.4%) 4 (4.0%) 0.86 Vasovagal, N (%) 4 (1.6%) 3 (2.1%) 1 (0.9%) 0.47 Gross Hematuria N (%) 134 (66.3%) 81 (68.6%) 53 (63.1%) 0.41 Duration, days, median (IQR) 14 (8.8–30) 14 (10–45) 14 (7–30) 0.13 Penile Burning N (%) 127 (62.9%) 76 (64.4%) 51 (60.7%) 0.59 Duration, days, median (IQR) 30 (10–90) 47 (10–90) 21 (7–60) 0.06 Penile Pain N (%) 73 (36.3%) 47 (39.8%) 26 (31.3%) 0.22 Duration, days, median (IQR) 30 (8–73.5) 40 (7–77) 21 (8.5–72) 0.48 Dysuria N (%) 52 (26.0%) 33 (28.2%) 19 (22.9%) 0.713 Duration, days, median (IQR) 30 (7.8–66.8) 30 (8.5–68.5) 21 (7–66) 0.48 Sloughing N (%) 36 (23.7%) 23 (24.5%) 13 (22.4%) 0.77 Duration, days, median (IQR) 21 (7–45) 21 (7–45) 22 (7–51) 0.97 Urinary retention 0.56 N (%) 32 (13.0%) 20 (14.1%) 12 (11.5%) Duration, days, median (IQR) 8 (7–18) 7 (8–14.8) 13 (6–26) Table 4 Occurrence and duration of postoperative adverse events. (Table presented.) Characteristic All patients Age < 65 years Age ≥ 65 years UTI, N (%) 8 (3.3%) 5 (3.5%) 3 (2.9%) 0.78 Sepsis, N (%) 0 (0%) 0 (0%) 0 (0%) Surgical retreatment, N (%) 19 (8.0%) 7 (5.1%) 12 (11.9%) 0.06 Vasovagal, N (%) 4 (1.6%) 3 (2.1%) 1 (0.9%) 0.47 Gross hematuria N (%) 134 (66.3%) 81 (68.6%) 53 (63.1%) 0.41 Duration, days, median (IQR) 14 (8.8–30) 14 (10–45) 14 (7–30) 0.13 Penile burning N (%) 127 (62.9%) 76 (64.4%) 51 (60.7%) 0.59 Duration, days, median (IQR) 30 (10–90) 47 (10–90) 21 (7–60) 0.06 Penile pain N (%) 73 (36.3%) 47 (39.8%) 26 (31.3%) 0.22 Duration, days, median (IQR) 30 (8–73.5) 40 (7–77) 21 (8.5–72) 0.48 Dysuria N (%) 52 (26.0%) 33 (28.2%) 19 (22.9%) 0.713 Duration, days, median (IQR) 30 (7.8–66.8) 30 (8.5–68.5) 21 (7–66) 0.48 Sloughing N (%) 36 (23.7%) 23 (24.5%) 13 (22.4%) 0.77 Duration, days, median (IQR) 21 (7–45) 21 (7–45) 22 (7–51) 0.97 Urinary retention 0.56 N (%) 32 (13.0%) 20 (14.1%) 12 (11.5%) Duration, days, median (IQR) 8 (7–18) 7 (8–14.8)